DIDRONEL
LOE Approachingetidronate disodium
NDAORALTABLETPriority Review
Approved
Sep 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIDRONEL (etidronate disodium) is a bisphosphonate small molecule oral tablet approved in 1977 for treating bone disorders, primarily Paget's disease and heterotopic ossification. It works by inhibiting osteoclast-mediated bone resorption and reducing abnormal bone turnover. The drug is typically used in patients with metabolic bone diseases or those at risk for abnormal bone formation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) suggests a defensive, mature-stage commercial team focused on retention and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and an LOE-approaching lifecycle stage, DIDRONEL offers limited career growth opportunities and suggests a wind-down or consolidation team. Roles on this product are typically maintenance-focused, emphasizing reimbursement defense, generic transition planning, and customer retention rather than innovation.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.